金达莱重金押宝医疗新兴赛道

Core Viewpoint - Jindalai, a water environment management company, is diversifying into the healthcare sector by investing in two medical technology firms, despite facing financial uncertainties in these target companies [1][5]. Group 1: Investment Details - Jindalai plans to invest CNY 280 million in Yunnan Jici Medical Technology Co., acquiring a 34% stake, focusing on autologous cell technology [2]. - The company will also invest CNY 30 million in Zhongke Hongtai Medical Technology Co., obtaining a 10% stake, which specializes in medical robotics [2]. - Both investments are seen as a strategic move to optimize Jindalai's industry structure and enhance its risk resilience [3]. Group 2: Financial Performance of Target Companies - Zhongke Hongtai reported revenues of approximately CNY 132,100 and CNY 102,600 for the last year and the first three quarters of this year, respectively, with net losses of CNY 11.4 million and CNY 5.5 million [5]. - Jici Medical's revenues were CNY 8.69 million and CNY 11.23 million for the same periods, with net profits of CNY 2.23 million and CNY 1.15 million [5]. - As of the end of Q3 this year, Jici Medical had negative net assets of CNY 31.53 million, indicating a state of insolvency [5]. Group 3: Valuation and Risks - The investments are made at a premium, with Jici Medical's assessed value at CNY 544 million, primarily due to the value of its patents and ongoing projects [6]. - The success of Jici Medical's business and financial outlook heavily relies on the successful clinical development and commercialization of its drug candidates [6].